Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Castle Biosciences (CSTL) Acquisitions (2022)

Castle Biosciences' Acquisitions history spans 1 years, with the latest figure at $305000.0 for Q3 2022.

On a quarterly basis, Acquisitions changed N/A to $305000.0 in Q3 2022 year-over-year; TTM through Dec 2023 was $305000.0, a 0.0% change, with the full-year FY2022 number at $27.0 million, changed N/A from a year prior.
Acquisitions hit $305000.0 in Q3 2022 for Castle Biosciences.
Over the last five years, Acquisitions for CSTL hit a ceiling of $305000.0 in Q3 2022 and a floor of $305000.0 in Q3 2022.